Cloxacillin versus pristinamycin for superficial pyodermas: A randomized, open-label, non-inferiority study

Dermatology

Volumn 210, Issue 4, 2005, Pages 370-374

  Chosidow, O ^a   Bernard, P ^c   Berbis, P ^d   Humbert, P ^e   Crickx, B ^b   Jarlier, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d HÔPITAL NORD   (France)

^e HÔPITAL SAINT JACQUES   (France)

Author keywords

Cloxacillin; Furuncle; Impetigo; Non inferiority clinical trial; Paronychia; Penicillin M; Pristinamycin; Pyoderma; Randomized clinical trial

Indexed keywords

CLOXACILLIN; PRISTINAMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; PRIVATE PRACTICE; PYODERMA; RANDOMIZED CONTROLLED TRIAL; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; CLOXACILLIN; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; PRISTINAMYCIN; PYODERMA; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 22144459810     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085113     Document Type: Article

References (8)

1. Bernard P, Vaillant L, Martin C, Beylot C, Quantin R, Touron D: Pristinamycine (Pyostacine 500®) versus oxacilline (Bristopen®) dans le traitement des pyodermites superficielles. Ann Dermatol Véné réol 1997;124:384-389.
2. Swartz MN: Skin and soft tissue infections; in Mandell GL, Bennett JE, Dolin R (eds): Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, ed 4. New York, Churchill-Livingstone, 1995, section I (72), pp 909-927.
3. Bouvet A, Aubry-Damon H, Pean Y: Emergence de la résistance aux macrolides des Streptococcus pyogenes ou streptocoques bêta- hémolytiques du groupe A. Bull Épidémiol Hebd 2004;32-33:154-155.
4. Lorette G, Beaulieu P, Bismuth R, Duru G, Guihard W, Lemaitre M, Janin N, Jarlier V: Infections cutanées communautaires: bactéries en cause et sensibilité aux antibiotiques. Ann Dermatol Véné réol 2003;130:723-728.
5. Rosenblatt JE, Kind AC, Brodie JL, Kirby WM: Mechanisms responsible for the blood level differences in isoxazolyl penicillins. Arch Intern Med 1968;121:345-348.
6. Jones B, Jarvis P, Lewis JA, Ebbutt AF: Trials to assess equivalence: The importance of rigorous methods. BMJ 1996;313:36-39.
7. EMEA, the European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products: Points to consider on the choice of non-inferiority margin. CPMP/EWP/2158/99 draft, February 26, 2004. http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf.
8. George A, Rubin G: A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract 2003;53:480-487.